Sanofi and GSK launch trial for COVID-19 protein-based vaccine
This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.
Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration(photo credit: REUTERS/ DADO RUVIC)ByREUTERS
